6,678 trials
Plaque Psoriasis
Primary: Percentage of Participants With Positive Anti-etanercept Binding Antibody Response During the Study — 3.8 percentage of participants
Tetanus · Poliomyelitis · Haemophilus Influenzae Type b
Primary: Number of Seroprotected Subjects Against Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T). — 7; 28; 10; 34 Participants
Smoking Cessation
Primary: Time to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936. — 0.29; 0.50; 0.29…
Coronary Artery Disease
Primary: P2Y12 Reaction Units (PRU) — 95; 164 PRU — p=0.022
Cerebrovascular Accident
Primary: Physical Function (Measured by the FIM-motor) — 47.1; 49.4; 73.1; 87.4 units on a scale
Pancreatitis · Diabetes
Primary: Insulin Independence — 42; 45 percentage of participants
Relapsing-Remitting Multiple Sclerosis
Primary: Percentage of Participants Reporting Overall Flushing Events During the First 4 Weeks of Treatment, as Assessed by the Modified Global Flushing Severity Scale (MGFSS)…
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 10 Participants
Cytomegalovirus Infections · Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 33; 37; 8 Participants
Variceal Bleeding
Primary: Proportion of Patients With Eradication of Esophageal Varices — 37; 23 Participants
Evidence of Liver Transplantation · Hyperglycemia · Rejection
Primary: Rejection of Liver Transplant — 17; 20 participants — p=0.709
Gallbladder Disease
Primary: Stress Response Inflammation Markers :Cortisol and C Reactive Protein (CRP) — 173.6; 289.5; 17; 17 pg/mL
Hemophilia A
Primary: Percentage of Participants With Clinically Significant Factor VIII Inhibitor Development — 0.00; 0.00 percentage of participants
Acute Coronary Syndrome · Sleep Disorder
Primary: Changes in Circulating Inflammatory Cytokines (Interleukin [IL]-1B, IL-6, IL-10, and Tumor Necrosis Alpha [TNF-α]) and Pro-coagulant Mediators (Soluble P-selectin and…
Osteoradionecrosis
Primary: Bone and/or Tissue Healing as Measured With the Classification of ORN Stages, Area of Bone Exposed (mm2) and Radiological Findings (OPG). — 14; 15; 13; 15 mm2